^
Association details:
| Biomarker: | BCR-ABL1 Q255K |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Excerpt:
The mutations, Leu248Val at the N-terminal and Ser417Tyr, Glu459Lys, and Phe486Ser at the C-terminal of the kinase domain have not previously been described….Lost CCR (17), dose increased to 800 mg, lost MCR (24), acquired imatinib resistance.
DOI:
https://doi.org/10.1182/blood-2002-09-2896
